Here are the DEF 14A proxy statements from Monopar Therapeutics Inc. (MNPR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MNPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNPR filings page.
Monopar Therapeutics Inc. is asking stockholders at its June 22, 2026 annual meeting to elect six directors, including new nominee Nicole Sweeny, approve executive pay on an advisory basis, adopt a new 2026 Stock Incentive Plan, and ratify BPM LLP as auditor.
Stockholders of record as of April 27, 2026, when 6,698,778 common shares were outstanding, may vote. The 2026 plan would add 600,000 new shares plus remaining and recycled shares from the prior plan, with new award capacity equal to 9.2% of fully diluted common stock as of March 31, 2026. The proxy also details director fees, substantial 2025 equity and cash compensation for executives, change-in-control severance protections, and pay-versus-performance disclosures comparing compensation actually paid to total shareholder return and net losses.